STOCK TITAN

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences clinical trial

Plus Therapeutics announced positive results from the FORESEE clinical trial evaluating CNSide™ Cerebrospinal Fluid Assay for leptomeningeal metastases (LM). The trial met its primary endpoint, with CNSide influencing treatment decisions in over 90% of cases. The assay showed 80% sensitivity in detecting tumor cells compared to 29% for standard CSF cytology. Notable findings include CNSide's ability to identify actionable mutations and its revelation of HER2 positivity in 60% of breast cancer patients with HER2-negative primary tumors, significantly impacting treatment strategies.

Plus Therapeutics ha annunciato risultati positivi dal trial clinico FORESEE che valuta il test CNSide™ per il leptomeningeal metastases (LM). Lo studio ha raggiunto il suo obiettivo primario, con CNSide che ha influenzato le decisioni terapeutiche in oltre il 90% dei casi. Il test ha mostrato un 80% di sensibilità nella rilevazione delle cellule tumorali rispetto al 29% della citologia standard del liquido cerebrospinale. Risultati notevoli includono la capacità di CNSide di identificare mutazioni trattabili e la rivelazione della positività per HER2 in 60% dei pazienti affetti da cancro al seno con tumori primari HER2-negativi, influenzando significativamente le strategie di trattamento.

Plus Therapeutics anunció resultados positivos del ensayo clínico FORESEE que evalúa el ensayo de líquido cefalorraquídeo CNSide™ para metástasis leptomeníngeas (LM). El ensayo alcanzó su objetivo primario, con CNSide influyendo en las decisiones de tratamiento en más del 90% de los casos. El ensayo mostró una sensibilidad del 80% en la detección de células tumorales en comparación con el 29% de la citología estándar del LCR. Hallazgos notables incluyen la capacidad de CNSide para identificar mutaciones accionables y su revelación de positividad para HER2 en 60% de los pacientes con cáncer de mama con tumores primarios HER2-negativos, impactando significativamente en las estrategias de tratamiento.

Plus Therapeutics는 지주막 전이 (LM)에 대한 CNSide™ 뇌척수액 분석을 평가하는 FORESEE 임상 시험에서 긍정적인 결과를 발표했습니다. 이 시험은 주요 목표를 달성했으며, CNSide는 90% 이상의 사례에서 치료 결정에 영향을 미쳤습니다. 이 시험은 표준 CSF 세포학의 29%에 비해 종양 세포를 검출하는 데 80%의 민감도를 보였습니다. 주목할 만한 발견으로는 실행 가능한 돌연변이를 식별하는 CNSide의 능력과 HER2 음성 주암을 가진 유방암 환자의 60%에서 HER2 양성 여부를 드러낸 점이 있으며, 이는 치료 전략에 상당한 영향을 미칩니다.

Plus Therapeutics a annoncé des résultats positifs de l'essai clinique FORESEE évaluant le test CNSide™ pour les métastases leptomeningées (LM). L'essai a atteint son objectif principal, avec CNSide influençant les décisions de traitement dans plus de 90% des cas. Le test a montré une sensibilité de 80% pour la détection des cellules tumorales contre 29% pour la cytologie standard du LCR. Les résultats notables incluent la capacité de CNSide à identifier des mutations exploitables et sa révélation de la positivité HER2 dans 60% des patientes atteintes de cancer du sein avec des tumeurs primaires HER2-négatives, ce qui impacte significativement les stratégies de traitement.

Plus Therapeutics hat positive Ergebnisse aus der FORESEE-Studie bekannt gegeben, die den CNSide™ Liquor cerebrospinalis-Test für leptomeningeale Metastasen (LM) bewertet. Die Studie erreichte ihr Hauptziel, wobei CNSide in über 90% der Fälle die Behandlungsentscheidungen beeinflusste. Der Test zeigte eine 80% Sensitivität bei der Erkennung von Tumorzellen im Vergleich zu 29% bei der standardmäßigen LCR-Zytologie. Bemerkenswerte Ergebnisse umfassen die Fähigkeit von CNSide, umsetzbare Mutationen zu identifizieren, sowie die Offenlegung einer HER2-Positivität bei 60% der Brustkrebspatientinnen mit HER2-negativen Primärtumoren, was die Behandlungsstrategien erheblich beeinflusst.

Positive
  • CNSide influenced treatment decisions in over 90% of cases, exceeding the 20% target
  • Demonstrated 80% sensitivity in detecting tumor cells vs 29% for standard cytology
  • Identified actionable mutations affecting 24% of therapeutic decisions
  • Showed high specificity with no false positives in non-LM patients
  • Revealed HER2 positivity in 60% of breast cancer patients with HER2-negative primary tumors
Negative
  • None.

Insights

The FORESEE clinical trial results represent a significant advancement in diagnosing and managing leptomeningeal metastases (LM). The CNSide CSF Assay demonstrated 80% sensitivity compared to just 29% with standard cytology - a substantial improvement that could revolutionize patient care.

The platform's ability to influence treatment decisions in 90% of cases and identify actionable mutations is particularly noteworthy. The discovery of HER2 positivity in 60% of breast cancer patients previously diagnosed as HER2-negative is a game-changing finding that could significantly impact treatment strategies and patient outcomes.

While this diagnostic advancement is promising for Plus Therapeutics' subsidiary CNSide Diagnostics, market adoption and reimbursement pathways will be critical factors for commercial success. The strong clinical validation could accelerate regulatory approvals and market penetration.

Prospective FORESEE trial of CNSide Cerebrospinal Fluid (CSF) Assay met key primary and secondary endpoints

CNSide CSF Assay influenced clinical management decisions in over 90% of leptomeningeal metastases (LM) cases

Assay demonstrated 2.8 times the diagnostic sensitivity vs. standard cytology

AUSTIN, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), will present data from the FORESEE trial showcasing the CNSide CSF Assay Platform’s utility in diagnosing and guiding clinical decision making for breast cancer and non-small cell lung cancer patients with LM. The data will be presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting November 21-24 in Houston, Texas.  

“Current gold standard CSF cytology lacks the sensitivity needed to reliably diagnose LM in most clinical situations and lacks utility for disease monitoring,” said Marc H. Hedrick, M.D., Plus Therapeutics’ President and Chief Executive Officer. “The FORESEE trial shows that CNSide may be a useful tool in accurately identifying all patients with LM, ruling out patients at risk, and enhancing the disease management and monitoring of LM.”

Key highlights:

  • The FORESEE trial achieved its primary endpoint, demonstrating that CNSide influenced treatment decisions in over 90% of cases evaluated, surpassing the predetermined 20% primary endpoint target
  • CNSide demonstrated enhanced sensitivity in detecting tumor cells (80%) vs. CSF cytology (29%) in patients with LM
  • CNSide identified actionable mutations in the CSF, such as HER2 amplification, influencing 24% of therapeutic selection decisions
  • CNSide exhibited high specificity, with no tumor cells detected in patients without LM
  • CNSide demonstrated improved Negative Predictive Value in ruling out LM (25%) vs. CSF cytology (10%)
  • CNSide revealed HER2 positivity in LM tumors in 60% of breast cancer patients with HER2-negative primary tumors, informing physician treatment strategies

The data will be presented on Sunday, November 24, at 10:15 a.m. CST in a session titled, “CSF Tumor Cell (CSF-TC) Detection, Quantification and Biomarker assessment Helps in Clinical Management of Breast Cancer and Non-Small Cell Lung Cancer Patients Having Leptomeningeal Disease (FORESEE Study, NCT-5414123),” by Priya Kumthekar, M.D., Associate Professor of Neurology and Hematology/Oncology, and Director of Brain Metastases Program at Northwestern, University, Chicago, Illinois.

About CNSide Diagnostic, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary clinical diagnostic laboratory assays, such as CNSid, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSid Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the clinical management of patients with leptomeningeal metastases. The Company is planning to commercialize CNSide in the U.S. in 2025.

About CNSide Test
The CNSide Cerebrospinal Fluid (CSF) Assay Platform consists of four laboratory developed tests (LDTs) used for diagnosis, treatment selection, and treatment monitoring of patients with Leptomeningeal Metastases (LM) from carcinomas or melanoma. The CNSide platform facilitates tumor cell detection / enumeration and biomarker identification using cellular assays (immunocytochemistry (ICC) and fluorescence in situ hybridization (FISH)) and molecular assays (next generation sequencing (NGS)). The CNSide CSF tumor cell enumeration LDT is currently being used in the ReSPECT-LM trial as an exploratory endpoint, and is anticipated to become commercially available in 2025.

About Leptomeningeal Metastases (LM)

LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid (CSF) and leptomeninges surrounding the brain and spinal cord. All malignancies originating from solid tumors, primary brain tumors, or hematological malignancies have this LM complication potential with breast cancer as the most common cancer linked to LM, with 3-5% of breast cancer patients developing LM. Additionally, lung cancer, GI cancers and melanoma can also spread to the CSF and result in LM. LM occurs in approximately 5% of people with cancer and is usually terminal with 1-year and 2-year survival of just 7% and 3%, respectively. The incidence of LM is on the rise, partly because cancer patients are living longer and partly because many standard chemotherapies cannot reach sufficient concentrations in the spinal fluid to kill the tumor cells; yet, there are no FDA-approved therapies specifically for LM patients, who often succumb to this complication within weeks to several months, if untreated.

About FORESEE Clinical Trial

The FORESEE Study is a multi-center, prospective clinical trial enrolled patients with Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM). Standard of Care methods to diagnose or assess the treatment response of LM (Clinical Evaluation, MRI and Cytology) have limited sensitivity and specificity. This creates challenges for physicians to manage LM or determine the best course of treatment. The goal of the FORESEE Study was to evaluate the performance of CNSide in monitoring the LM's response to treatment and to assess the impact of CNSide on treatment decisions made by physicians.

About Rhenium (186Re) obisbemeda

Rhenium (186Re) obisbemeda is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. Rhenium (186Re) obisbemeda has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. Rhenium (186Re) obisbemeda is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT).

About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.

Cautionary Statement Regarding Forward-Looking Statements
This presentation contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the uses and benefits of the CNSide CSF Assay Platform, and predicted timeline for commercialization of the CNSide CSF tumor cell enumeration test.

The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company’s product candidates and therapies; the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash to fund its operations in the near term and long term, on terms acceptable to us or at all; the outcome of the Company’s partnering/licensing efforts; risks associated with laws or regulatory requirements applicable to the Company, including the ability to come into compliance with The Nasdaq Capital Market listing requirements; market conditions; product performance; litigation or potential litigation; competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; manufacturing and supply chain risks; and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2023, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor Contact
Charles Y. Huang, MBA
Director of Capital Markets and Investor Relations
Office: (202)-209-5751 | Direct (301)-728-7222
chuang@plustherapeutics.com


FAQ

What were the main results of Plus Therapeutics (PSTV) FORESEE trial for CNSide?

The FORESEE trial showed CNSide influenced treatment decisions in over 90% of cases and demonstrated 80% sensitivity in detecting tumor cells compared to 29% for standard CSF cytology.

How does CNSide's detection rate compare to standard CSF cytology for leptomeningeal metastases?

CNSide demonstrated 2.8 times higher sensitivity (80%) compared to standard CSF cytology (29%) in detecting tumor cells in patients with leptomeningeal metastases.

What percentage of treatment decisions were influenced by CNSide's mutation detection in the FORESEE trial?

CNSide's identification of actionable mutations in the CSF influenced 24% of therapeutic selection decisions in the trial.

What was the HER2 positivity finding in Plus Therapeutics' (PSTV) FORESEE trial?

CNSide revealed HER2 positivity in LM tumors in 60% of breast cancer patients who had HER2-negative primary tumors, which influenced physician treatment strategies.

PLUS THERAPEUTICS, Inc.

NASDAQ:PSTV

PSTV Rankings

PSTV Latest News

PSTV Stock Data

5.73M
5.57M
2.34%
11.39%
0.89%
Biotechnology
Surgical & Medical Instruments & Apparatus
Link
United States of America
AUSTIN